- Home
- SCNX vs BLRX Comparison
SCNX vs BLRX Comparison
Compare SCNX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- BLRX
- Stock Information
- Founded
- SCNX 2010
- BLRX 2003
- Country
- SCNX United States
- BLRX Israel
- Employees
- SCNX N/A
- BLRX N/A
- Industry
- SCNX Other Pharmaceuticals
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- BLRX Health Care
- Exchange
- SCNX Nasdaq
- BLRX Nasdaq
- Market Cap
- SCNX 21.2M
- BLRX 17.1M
- IPO Year
- SCNX 2020
- BLRX 2011
- Fundamental
- Price
- SCNX $0.69
- BLRX $3.86
- Analyst Decision
- SCNX
- BLRX Strong Buy
- Analyst Count
- SCNX 0
- BLRX 2
- Target Price
- SCNX N/A
- BLRX $19.00
- AVG Volume (30 Days)
- SCNX 186.1K
- BLRX 52.2K
- Earning Date
- SCNX 11-05-2025
- BLRX 11-24-2025
- Dividend Yield
- SCNX N/A
- BLRX N/A
- EPS Growth
- SCNX N/A
- BLRX N/A
- EPS
- SCNX N/A
- BLRX N/A
- Revenue
- SCNX $128,202.00
- BLRX $17,251,000.00
- Revenue This Year
- SCNX N/A
- BLRX N/A
- Revenue Next Year
- SCNX N/A
- BLRX N/A
- P/E Ratio
- SCNX N/A
- BLRX N/A
- Revenue Growth
- SCNX N/A
- BLRX 1.19
- 52 Week Low
- SCNX $0.67
- BLRX $2.30
- 52 Week High
- SCNX $9.55
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- SCNX 28.59
- BLRX 47.14
- Support Level
- SCNX $0.67
- BLRX $3.70
- Resistance Level
- SCNX $0.89
- BLRX $4.56
- Average True Range (ATR)
- SCNX 0.08
- BLRX 0.33
- MACD
- SCNX 0.01
- BLRX -0.01
- Stochastic Oscillator
- SCNX 4.14
- BLRX 29.29
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.